Rituximab: An innovative therapy for non-Hodgkin's lymphoma

American Journal of Health-System Pharmacy

Volumn 58, Issue 3, 2001, Pages 215-232

  Wood, A M ^a  

^a Clinical Specialist   (United States)

Author keywords

Antibodies; Antineoplastic agents; Clinical studies; Epidemiology; Lymphoma; Mechanism of action; Pharmacokinetics; Rituximab; Toxicity

Indexed keywords

CD20 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; PREDNISONE; RITUXIMAB; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHILL; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INFUSION; DRUG SAFETY; FATIGUE; FEVER; HEADACHE; HEART ARRHYTHMIA; HISTOLOGY; HUMAN; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SYNDROME DELINEATION; URTICARIA;

EID: 0035253686     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/58.3.215     Document Type: Review

References (81)

1. Cancer statistics, 1999
2. Non-Hodgkin's lymphomas
3. Epidemiology of Hodgkin's disease and non-Hodgkin's lymphoma
4. Distribution of non-Hodgkin's lymphomas in the United States between 1950 and 1975
5. Clinical manifestations and staging of and therapy for nan-Hodgkin's lymphomas
6. Lymphomas
7. Adult non-Hodgkin's lymphomas
8. Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma
9. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas
10. Chromosomal translocations in lymphoid malignancies reveal novel protooncogenes
11. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells
12. Early achievement of molecular complete remission assayed by PCR predicts failure free survival in low grade follicular lymphomas
13. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation
14. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow
15. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma
16. Lymphoma classification proposal: Clarification
17. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage
18. The natural history of initially untreated low-grade non-Hodgkin's lymphomas
19. Histologic conversion in the non-Hodgkin's lymphomas
20. Non-Hodgkin's lymphomas: Current classification and management
21. Natural history of and therapy for the indolent non-Hodgkin's lymphomas
22. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
23. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma
24. Applicability of the internal index for aggressive lymphomas to patients with low-grade lymphoma
25. The natural history of low grade non-Hodgkin's lymphoma and the impact of a no initial treatment policy on survival
26. The treatment of indolent lymphomas: Watchful waiting vs aggressive combined modality treatment
27. The treatment of advanced stage favorable histology non-Hodgkin's lymphoma: A preliminary report of a randomized trial comparing single agent chemotherapy, combination chemotherapy, and whole body irradiation
28. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma
29. Efficacy of cyclophosphamide and fludarabine as first-line therapy of low-grade non-Hodgkin's lymphoma
30. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: A multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte
31. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma
32. Long-term results of low dose total body irradiation for advanced non-Hodgkin lymphoma
33. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma
34. On immunity with specific reference to cell life
35. Continuous cultures of fused cells secreting antibody of pre-defined specificity
36. Monoclonal antibody-based therapies for hematologic malignancies
37. Use of rituximab, the new FDA-approved antibody
38. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
39. Newer treatments for non-Hodgkin's lymphoma: Monoclonal antibodies
40. Unconjugated monoclonal antibody therapy of lymphoma
41. Glennie MJ Overview of monoclonal antibody-based targets for antibody therapy of lymphoma
42. Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation
43. Lymphocytic lymphomas
44. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains
45. CD20: A regulator of cell-cycle progression of B lymphocytes
46. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia
47. IDEC-C2B8: Results of a Phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
48. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma
49. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
50. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
51. Efficacy controls and long-term follow-up of patients treated with rituximab for relapsed or refractory, low-grade or follicular non-Hodgkin's lymphoma
52. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a Phase II trial of rituximab
53. Rituximab: Phase II retreatment study in patients with low-grade or follicular non-Hodgkin's lymphoma
54. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma
55. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter Phase II study
56. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
57. Phase II pilot study of the safety and efficacy of rituximab in combination with CHOP chemotherapy in patients with previously untreated intermediate- or high-grade NHL
58. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma
59. A multicenter Phase II study of iodine-131 anti-B1 antibody (Bexxar) in patients with chemotherapy-relapsed/refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphoma
60. Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia
61. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma
62. IDEC-Y2B8 radioimmunotherapy: Responses in patients with splenomegaly
63. Phase II clinical trial of bolus infusion anti-B4-blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma
64. Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma
65. The anti-tumor effect of monoclonal anti-CD20 antibody therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma cell lines
66. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs
67. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma
68. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
69. Response criteria for NHL: Importance of "normal" Lymph node size and correlations with response
70. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: Association with increased infusion-related side effects and rapid blood tumor clearance
71. Tumor lysis syndrome: Pathogenesis and management
72. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma
73. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)
74. Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma in the U.K.
75. Progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation has a high response rate to rituximab
76. In vivo purging and adjuvant immunotherapy with rituximab during PBSC transplant for NHL
77. In vivo purging of circulating CD34+ progenitor cells in low-grade lymphoma with rituximab and high-dose chemotherapy